Evidence map›Paper›PMID 37152809›Full record

ArticleNeuro-oncology advances

A single-institution retrospective analysis of pathologically determined malignant transformation in

Vicki Liu, Ethan A Wetzel, Blaine S C Eldred, Serendipity Zapanta Rinonos, Terry J Prins, Negar Khanlou, Linda M Liau, Robert Chong, Phioanh L Nghiemphu, Timothy F Cloughesy and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Vicki LiuDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Ethan A WetzelDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Blaine S C EldredDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Serendipity Zapanta RinonosDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Terry J PrinsDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Negar KhanlouDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Robert ChongDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Phioanh L NghiemphuDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Benjamin M EllingsonDepartment of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Albert LaiDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
EPA EP-C-15-003NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA270027NCI NIH HHS R01 CA279984NCI NIH HHS T32 CA009056
6 · The paper itself

Abstract

Background: Lower-grade Methods: We identified 193 Results: Time to MT is longer in grade 2 oligodendroglioma (G2 Oligo) than in grade 2 astrocytoma (G2 Astro) (HR = 0.46, Conclusion: Our study expands the understanding of MT to improve

Indexed as

gliomaIDH1/2malignant transformationprogressiontumor grade

Identifiers

PMID37152809
PMCPMC10162112
OpenAlexW4364359335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.